The clinical impact of ABCB1 polymorphisms on the treatment of psychiatric diseases

Current Pharmaceutical Design

Volumn 17, Issue 26, 2011, Pages 2843-2851

  Rosenhagen, Marcus C ^a   Uhr, Manfred ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

ABCB1 transporter; P glycoprotein; Pharmacogenetic; Single nucleotide polymorphism

Indexed keywords

AMISULPRIDE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BUSPIRONE; CARBAMAZEPINE; CITALOPRAM; CLOZAPINE; DOXEPIN; FLUOXETINE; GLYCOPROTEIN P; HALOPERIDOL; LAMOTRIGINE; LITHIUM; MELPERONE; MIRTAZAPINE; MOOD STABILIZER; MULTIDRUG RESISTANCE PROTEIN 1; NEUROLEPTIC AGENT; NORFLUOXETINE; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PHENYTOIN; RISPERIDONE; SULPIRIDE; TRAZODONE; TRIMIPRAMINE; UNINDEXED DRUG; VENLAFAXINE;

BIPOLAR DISORDER; DEPRESSION; DRUG EFFICACY; DRUG PENETRATION; DRUG TRANSPORT; DRUG UPTAKE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; MANIA; MENTAL DISEASE; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

EID: 80053505869     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211797440140     Document Type: Review

References (68)

1. Uhr M, Tontsch A, Namendorf C, et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 2008; 57: 203-9.
2. Sarginson JE, Lazzeroni LC, Ryan HS, Ershoff BD, Schatzberg AF, Murphy GM Jr. ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression. Pharmacogenet Genomics 2010; 20(8): 467-75.
3. Bosch I, Croop JM. P-glycoprotein structure and evolutionary homologies. Cytotechnology 1998; 27: 1-30.
4. Doran A, Obach RS, Smith BJ, et al. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 2005; 33(1): 165-74.
5. Uhr M, Steckler T, Yassouridis A. Penetration of amitriptyline, but not of fluoxetine, into the brain is enhanced in mice with bloodbrain- barrier deficiency due to Mdr1a P-glycoprotein gene disruption. J Neuropsychopharmacol 2000; 22: 380-387.
6. Uhr M, Grauer MT, Holsboer F. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry 2003; 54: 840-846.
7. Uhr M, Grauer MT. Abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. J Psychiatr Res 2003; 37: 179-185.
8. Linnet K, Ejsing TP. A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs. Euro Neuropsychopharmacol 2008; 18: 157-69.
9. Urquhart BL, Kim RB. Blood-brain barrier transporters and response to CNS-active drugs. Eur J Clin Pharmacol 2009; 65: 1063-70.
10. Gex-Fabry M, Eap CB, Oneda B, et al. CYP2D6 and ABCB1 Genetic Variability: Influence on Paroxetine Plasma Level and Therapeutic Response. Ther Drug Monit 2008; 30(4): 474-82.
11. Uhr M, Namendorf C, Grauer MT, Rosenhagen M, Ebinger M. Pglycoprotein is a factor in the uptake of dextromethorphan, but not of melperone, into the mouse brain: evidence for an overlap in substrate specificity between P-gp and CYP2D6. J Psychopharm 2004; 18(4): 509-15.
12. Nikisch G, Baumann P, Oneda B, et al. Cytochrome P450 and ABCB1 genetics: association with quetiapine and norquetiapine plasma and cereprospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study. J Psychopharmacol 2010 (Epub ahead of print).
13. Ejsing TB, Hasselstrom J, Linnet K. The influence of Pglycoprotein on cerebral and hepatic concentrations of nortriptyline and its metabolites. Drug Metabol Drug Interact 2006; 21: 139-62.
14. Wang JS, Zhu HJ, Gibson BB, Markowitz JS, Donovan JL, DeVane CL. Sertraline and its metabolite desmethylsertraline, but not Bupropion or its three major metabolites, have high affinity for P-glycoprotein. Bio Pharm Bull 2008; 31: 231-4.
15. Roberts RL, Joyce PR, Mulder RT, Begg EJ, Kennedy MA. A common P-glycoprotein polymorphism is associated with nortriptyline- induced postural hpotension in patients treated for major depression. The Pharmacog J 2002; 2: 191-6.
16. Kuzman MR, Medved V, Bozina N, Grubisin J, Jovanovic N, Sertic J. Association study of MDR1 and 5-HT2C genetic polymorphisms and antipsychotic-induced metabolic disturbances in female patients with schizophrenia. Pharmacogenomics J 2011; 11(1): 35-44.
17. Dong C, Wong ML, Licinio J. Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican- Americans. Mol Psychiatry 2009; 14: 1105-18.
18. Qian W, Homma M, Itagaki F, et al. MDR1 Gene Polymorphism in Japanese Patients with Schizophrenia and Mood Disorders Including Depression. Biol Pharm Bull 2006; 29(12): 2446-50.
19. Owen A, Chandler B, Back DJ, Khoo SH. Expression of pregnane- X-receptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA. Antivir Ther 2004; 9(5): 819-21.
20. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. Pglycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996; 97: 2517-24.
21. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 2003; 305: 197-204.
22. Maines LW, Antonetti DA, Wolpert EB, Smith CD. Evaluation of the role of P-glycoprotein in the uptake of paroxetine, clozapine, phenytoin and carbamazapine by bovine retinal endothelial cells. Neuropharmacology 2005; 49: 610-7.
23. Kannan P, John C, Zoghbi SS, et al. Imaging the Function of PGlycoprotein with Radiotracers: Pharmacokinetics and In Vivo Applications. Clin Pharmacol Ther 2009; 86: 368-77.
24. Grauer MT, Uhr M. P-glyocprotein reduces the ability of amitriptyline metabolites to cross the blood-brain barrier in mice after a 10-day administration of amitriptyline. J Psychopharmacol 2004; 18(1): 66-74.
25. Uhr M, Grauer MT, Yassouridis A, Ebinger M. Blood-brain barrier penetration and pharmacokinetics of amitriptyline and its metabolites in p-glycoprotein (abcb1ab) knockout mice and controls. J Psychiatr Res 2007; 41: 179-88.
26. Ejsing TB, Linnet K. Influence of P-glycoprotein inhibition on the distribution of the tricyclic antidepressant nortriptyline over the blood-brain barrier. Hum Psychopharmacol 2005; 20(2): 149-53.
27. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, et al. Structure of P-Glycoprotein Reveals a Molecular Basis for Poly- Specific Drug Binding. Science 2009; 323: 1718-22.
28. Boulton DW, DeVane CL, Liston HL, Markowitz JS. In vitro Pglycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002; 71(2): 163-9.
29. Kirschbaum KM, Henken S, Hiemke C, Schmitt U. Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice. Behav Brain Res 2008; 188(2): 298-303.
30. Liu X, Chen C, Smith BJ. Progress in Brain Penetration Evaluation in Drug Discovery and Development. J Pharmacol Exp Ther 2008; 325: 349-56.
31. Kirschbaum KM, Uhr M, Holthoewer D, et al. Pharmacokinetics of acute and sub-chronic aripiprazole in P-glycoprotein deficient mice. Neuropharmacology 2010; 59: 474-9.
32. Wang JS, Zhu HJ, Donovan L, et al. Aripiprazole brain concentration is altered in P-glycoprotein deficient mice. Schizophrenia Research 2009; 110: 90-4.
33. Wang JS, Taylor R, Ruan Y, Donovan JL, Markowitz JS, De Vane CL. Olanzapine Penetration into Brain is Greater in Transgenic Abcb 1a P-glycoprotein-Deficient Mice than FVBI (Wild-Type) Animals. Neuropsychopharmacol 2004; 29: 551-7.
34. Iwaki K, Sakaeda T, Kakumoto M, et al. Haloperidol is an inhibitor but not substrate for MDR1 /P-glycoprotein. J. Pharm Pharmacol 2006; 58: 1917-22.
35. Ejsing TB, Pedersen AD, Linnet K. P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug-drug interaction experiments. Hum Psychopharmacol 2005; 20(7): 493-500.
36. Schmitt U, Abou El-Ela A, Guo LJ, et al. Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp). J Neural Transm 2006; 113(7): 787-801.
37. Cho HY, Yoo HD, Lee YB. Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of levosulpiride in healthy subjects. Neuroscience 2010; 169(1): 378-87.
38. El Ela AA, Härtter S, Schmitt U, Hiemke C, Spahn-Langguth H, Langguth P. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds - implications for pharmacokinetics of selected substrates. J Pharm Pharmacol 2004; 56(8): 967-75.
39. Robey RW, Lazarowski A, Bates SE. P-Glycoprotein - a clinical target in drug-refractory epilepsy. Mol Pharmacol 2008; 73:1343-1346.
40. Baltes S, Fedrowitz M, Tortos CL, Potschka H, Loscher W. Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J Pharmacol Exp Ther 2007; 320: 331-43.
41. Crowe A, Teoh Yee-Khuan. Limited P-glycoprotein mediated efflux for anti-epileptic drugs. J Drug Targeting 2006; 14(5): 291-300.
42. Haerian BS, Lim KS, Mohamed EHM, et al. Lack of association of ABCB1 and PXR polymorphisms with response to treatment in epilepsy. Seizure 2011 (Epub ahead of print).
43. Luna-Tortos C, Fedrowitz M, Löscher Wolfgang. Evaluation of transport of common antiepileptic drugs by human multidrug resistance- associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology 2010; 58: 1019-32.
44. Haerian BS, Roslan H, Raymond AA, et al. ABCB1 C3435T polymorphism and the risk of resistance to antiepileptic drugs in epilepsy: A systematic review and meta-analysis. Seizure 2010; 19: 339-46.
45. Haerian BS, Lim KS, Tan CT, Raymond AA, Mohamed Z. Association of ABCB1 gene polymorphisms and their haplotypes with response to antiepileptic drugs: a systematic review and metaanalysis. Pharmacogenomics 2011 (Epup ahead of print).
46. Hung CC, Chen CC, Lin CJ, Liou HH. Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics 2008; 18(5): 390-402.
47. Kimchi-Sarfaty C, Oh JM, Kim IW, et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007; 315(5811): 525-8.
48. Kato M, Fukuda T, Serretti A, et al. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 398-404.
49. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000; 23(5): 477-501.
50. Karssen AM, Meijer OC, van der Sandt IC, et. al. Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain. Endocrinology 2001; 142(6): 2686-94.
51. Perroud N, Bondolfi G, Uher R, et. al. Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample. Pharmacogenomics 2011; 12(3): 365-77.
52. Binder EB, Salyakina D, Lichtner P, et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 2004; 36: 1319-25.
53. Rosenhagen M and Uhr M. Single Nucleotide Polymorphism in the Drug Transporter Gene ABCB1 in Treatment- Resistant Depression. Clinical Practice. J Clin Psychopharmacol 2010; 30(2): 209-11.
54. Mihaljevic-Peles A, Bozina N, Sagud M, Rojnic KM, Lovric M. MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1439-44.
55. Perlis RH, Fijal B, Dharia S, Heinloth AN, Houston JP. Failure to replicate genetic associations with antidepressant treatment response in duloxetine-treated patients. Biol Psychiatry 2010; 67(11): 1110-3.
56. Ruike Z, Junhua C, Wenxing P. In vitro and in vivo evaluation of the effects of duloxetine on P-gp function. Hum Psychopharmacol 2010; 25(7-8): 553-9.
57. Menu P, Gressier F, Verstuyft C, Hardy P, Becquemont L, Corruble E. Antidepressants and ABCB1 Gene C3435T Functional Polymorphism: A Naturalistic Study. Neuropsychobiology 2010; 62: 193-7.
58. Weber CC, Kressmann S, Ott M, Fricker G, Müller WE. Inhibition of P-Glycoprotein Function by Several Antidepressants may not Contribute to Clinical Efficacy.
59. Nikisch G, Eap CB, Baumann P. Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: A pilot study. Pharmacol Res 2008; 58: 344-7.
60. Lin KM, Chiu YF, Tsai IJ, et al. ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment. Pharmacogenet Genomics 2011; 21(4):163-170.
61. Vanoli A, Lane CJ, Harrison C, et al. Adequacy of venlafaxine dose prescribing in major depression and hospital resources implications. Psychopharmacology 2008; 22: 434-440.
62. Bozina N, Kuzman MR, Medved V, Jovanovic N, Sertic J, Hotujac L. Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients. J Psychiatr Res 2008; 42(2): 89-97.
63. Kastelic M, Koprivsek J, Plesnicar BK, et al. MDR1 gene polymorphisms and response to acute risperidone treatment. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2010; 34: 387-92.
64. Xing Q, Gao R, Li H, Feng G, Xu M, Duan S et al. Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics 2006; 7: 987-93.
65. Haerian BS, Lim KS, Tan HJ, et al. Association between ABCB1 polymorphism and response to sodium valproate treatment in Malaysian epilepsy patients. Epileptic Disord. 2011; 13(1): 65-75.
66. Trivedi MH, Rush AJ, Wisniewksi SR, et al. Evaluation of outcomes with Citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163(1): 28-40.
67. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and Longer- Term Outcomers in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report. Am J Psychiatry 2006; 163(11): 1905-17.
68. Murray CJL, Lopez AD. Evidence-Based Health Policy-Lessons from the Global Burden of Disease Study. Science 1996; 274: 740-3.